Boston Scientific Corp.


Market Cap$108.94B

Compare Boston Scientific

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Boston Scientific Corp.Boston Scientific Corp.61.70%9%7.50.5
marketMarket Avg54.31.27%32%-1.3
HealthcareHealthcare Avg39.11.36%17%7.21.3

Earnings Call Q4 2023

January 31, 2024 - AI Summary

Boston Scientific reported strong Q4 and full-year 2023 results, with operational sales growth of 15% in Q4 and 13% for the full year.
The company exceeded its financial goals for the year, with organic sales growth of 12% and adjusted EPS growth of 20%.
For 2024, Boston Scientific expects organic revenue growth of 8% to 9%, driven by ongoing momentum across its business units and regions.

Exclusive for Stockcircle Pro members

Sign upSign Up

Target Price by Analysts

7.7% upsideBoston Scientific Target Price DetailsTarget Price

Current Fair Value

62% downside

Overvalued by 62% based on the discounted cash flow analysis.

Share Statistics

Market cap$108.94 Billion
Enterprise Value$117.23 Billion
Dividend Yield$0.0 (0.0%)
Earnings per Share$1.2
Outstanding Shares1,470,179,843
Avg 30 Day Volume7,246,230


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio61.72
Price to Sales7.46
Price to Book Ratio5.73
Enterprise Value to Revenue7.97
Enterprise Value to EBIT46.39
Enterprise Value to Net Income66
Total Debt to Enterprise0.09
Debt to Equity0.53

Revenue Sources

No data

ESG Score

No data

About Boston Scientific Corp.

2,020 employees
CEO: Michael Mahoney